AA
IRON icon

AlphaCentric Advisors’s Disc Medicine IRON Stock Holding History

AlphaCentric Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
3,972
+216
+6% +$15K 0.25% 125
2025
Q4 		$298K Buy
+3,756
New +$317K 0.3% 105

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

AlphaCentric Advisors's IRON Position: Q1 2026 in Review

AlphaCentric Advisors increased its Disc Medicine (IRON) stake by 5.8% in Q1 2026, buying an estimated $15K and bringing the position to 3,972 shares worth $254K. The position accounts for 0.25% of the portfolio, ranked #125.

AlphaCentric Advisors first reported a position in IRON in Q4 2025 and has held it in 2 quarters since. The position peaked at $298K in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • AlphaCentric Advisors held 3,972 shares of Disc Medicine worth $254K as of Q1 2026.
  • AlphaCentric Advisors bought 216 Disc Medicine shares in Q1 2026, an estimated $15K.
  • Disc Medicine made up 0.25% of AlphaCentric Advisors's portfolio in Q1 2026, its #125 holding.
  • AlphaCentric Advisors first reported a position in Disc Medicine in Q4 2025 and has held it in 2 quarters since.
  • AlphaCentric Advisors's Disc Medicine position peaked at $298K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.